anti-FcRL5

anti-FcRL5 refers to monoclonal antibodies or therapeutic agents targeting Fc receptor-like 5 (FcRL5, also known as FcRH5, CD307e, or IRTA2). FcRL5 is a cell surface receptor expressed predominantly on B-lineage cells, including mature B cells and plasma cells, and is often overexpressed in multiple myeloma and other B-cell malignancies. In the context of oncology, anti-FcRL5 antibodies are being investigated as antibody-drug conjugates (ADCs), bispecific antibodies (such as cevostamab), and chimeric antigen receptor (CAR) T-cell therapies to selectively target and eliminate malignant B cells. Additionally, preclinical research suggests that FcRL5 acts as an inhibitory receptor on memory B cells, and blocking FcRL5 can restore B-cell proliferative capacity and enhance antitumor immunity in solid tumors.

Other names

FcRH5 antibodyFcRH-5 antibodyFcRH 5 antibodyFcRL5 antibodyFcRL-5 antibodyFcRL 5 antibodyanti-CD307eanti-CD-307eanti-CD 307eanti-CD307e antibodyanti-CD-307e antibodyanti-CD 307e antibodyanti-FCRL5anti-FCRL-5anti-FCRL 5anti-FCRL5 antibodyanti-FCRL-5 antibodyanti-FCRL 5 antibodyanti-FcRH5anti-FcRH-5anti-FcRH 5anti-FcRH5 antibodyanti-FcRH-5 antibodyanti-FcRH 5 antibody